Angiotensin II Receptor Antagonist in Pregnancy
نویسندگان
چکیده
منابع مشابه
Fimasartan, a novel angiotensin II receptor antagonist.
Fimasartan (Kanarb®), an angiotensin II receptor antagonist with selectivity for the AT1 receptor subtype, is a pyrimidinone-related heterocyclic compound that was developed by Boryung Pharm. Co., Ltd. Among numerous synthetic derivatives, fimasartan was chosen as a new drug candidate through in vitro and in vivo screening studies. Pharmadynamic-pharmacokinetic properties and safety profiles we...
متن کاملEprosartan mesylate, an angiotensin II receptor antagonist
The title compound, eprosartan mesylate {systematic name: 2-butyl-1-(4-carb-oxy-benz-yl)-5-[(E)-2-carb-oxy-3-(thio-phen-2-yl)prop-1-en-yl]-1H-imidazol-3-ium methane-sulfonate}, C(23)H(25)N(2)O(4)S(+)·CH(3)O(3)S(-), one of the angiotensin II-receptor antagonists, is effective in regulating hypertension, induced or exacerbated by angiotensin II, and in the treatment of congestive heart failure, r...
متن کاملeffect of angiotensin ii type 1 receptor antagonist, losartan on inflammatory factor in atherosclerotic rabbits
materials and methods: 32 new zealand rabbits were randomly divided into three groups: control group, high-cholesterol group and losartan group. the level of weights, serum lipid levels and inflammatory factors, such as il-6 and hs c-reactive protein were detected before the losartan intervention and two months after the losartan intervention respectively. the content of angii was detected on l...
متن کاملLong-Term Consequences of Fetal Angiotensin II Receptor Antagonist Exposure
Fetal angiotensin II receptor antagonist exposure is associated with major complications and even death when administered during pregnancy. Neonates frequently require intensive care treatment, and mortality is high. Despite this well-known risk potential, a considerable number of women still receive angiotensin II receptor antagonists during pregnancy to treat arterial hypertension. Although c...
متن کاملClinical overview of irbesartan: a new angiotensin II receptor antagonist.
Irbesartan is an angiotensin II receptor (AT1 subtype) antagonist that has been extensively studied in the Bristol-Myers Squibb/Sanofi clinical development program. As shown in seven placebo controlled clinical trials, irbesartan provides clinically significant dose related reductions in blood pressure in patients with mild-to-moderate hypertension. Once daily dosing provides full 24 h blood pr...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Perinatology
سال: 2003
ISSN: 0743-8346,1476-5543
DOI: 10.1038/sj.jp.7211011